Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702271 · ClinicalTrials.gov registry record · NA
Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 458
- Enrollment target
NCT02702271 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 458 participants.
The verdict
NCT02702271, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 458 participants
- Enrollment target
Study Summary
The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are eligible for long-term anti-coagulation therapy to reduce the risk of stroke but who have a rationale to seek a non-pharmacologic alternative.
Interventions
- DEVICE WATCHMAN FLX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2021-03-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702271
The ClinicalTrials.gov registry entry for NCT02702271 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WATCHMAN FLX is the first listed.
NCT02702271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02702271 about?
NCT02702271 is a clinical study titled "Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology". The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are eligible for long-term anti-coagulation therapy to reduce the risk of ...
What is the current status of trial NCT02702271?
This trial is currently completed. It is a NA study. The enrollment target is 458 participants. The study started on 2018-05-07. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT02702271?
The interventions under investigation include: WATCHMAN FLX (DEVICE).
Who is sponsoring clinical trial NCT02702271?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.